Where is bcg vaccine given

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: The BCG vaccine is typically administered via intradermal injection in the upper arm's deltoid region, specifically at the insertion of the deltoid muscle. In countries with high tuberculosis prevalence, it's given to infants shortly after birth, with the World Health Organization recommending a single dose of 0.05 ml for newborns and 0.1 ml for older children and adults.

Key Facts

BCG vaccine is administered via intradermal injection in the deltoid region of the upper arm
Standard dose is 0.05 ml for newborns and 0.1 ml for older children/adults
WHO recommends administration shortly after birth in high TB burden countries
First human BCG vaccination occurred in 1921 in Paris
BCG provides 50-80% protection against severe childhood TB forms

Overview

The Bacille Calmette-Guérin (BCG) vaccine is the only licensed vaccine for tuberculosis prevention, developed between 1908 and 1921 by French bacteriologists Albert Calmette and Camille Guérin. Derived from an attenuated strain of Mycobacterium bovis, this live attenuated vaccine has been administered to over 4 billion people worldwide since its introduction. The vaccine's development involved 230 serial passages of the bovine tuberculosis bacillus over 13 years, creating a strain that provides immunity without causing disease in immunocompetent individuals.

BCG vaccination policies vary significantly by country based on tuberculosis epidemiology and risk assessment. In high-burden countries, the World Health Organization recommends universal vaccination of all infants as soon as possible after birth. In low-incidence countries like the United States, vaccination is typically reserved for specific high-risk groups including healthcare workers, laboratory personnel, and children with increased exposure risk. The vaccine's efficacy against pulmonary tuberculosis in adults varies widely (0-80%) but provides consistent protection against severe childhood forms of the disease.

How It Works

The BCG vaccine stimulates cellular immunity through a complex immune response that provides protection against Mycobacterium tuberculosis.

Administration Method: The vaccine is administered via intradermal injection using a short-beveled needle inserted at a 10-15 degree angle. The standard injection site is the deltoid region of the upper arm at the insertion of the deltoid muscle, approximately one-third of the way down from the shoulder to the elbow. Healthcare providers must ensure proper technique to avoid subcutaneous injection, which can cause abscess formation.
Dosage Specifications: The standard dose is 0.05 ml for newborns and 0.1 ml for older children and adults. The vaccine contains between 2-8 × 10^5 colony-forming units per dose when reconstituted. Proper storage at 2-8°C is critical, as the live attenuated vaccine loses potency if frozen or exposed to light for extended periods.
Immune Response: BCG induces a delayed-type hypersensitivity response that typically appears 2-6 weeks post-vaccination. The vaccine stimulates CD4+ and CD8+ T-cells, creating immunological memory against mycobacterial antigens. This response leads to the characteristic local reaction including induration, erythema, and eventual ulceration that heals with scarring over 3-6 months.
Vaccination Timing: In high-burden countries, the WHO recommends administration as soon as possible after birth, ideally within the first week of life. Studies show vaccination within 24 hours of birth provides optimal protection. In settings with high HIV prevalence, vaccination may be delayed until HIV status is confirmed, as BCG can cause disseminated disease in HIV-infected infants.

Key Comparisons

Feature	Standard BCG Administration	Alternative Approaches
Injection Site	Deltoid region of upper arm	Thigh (historical use, now discouraged)
Administration Age	Shortly after birth (0-1 week)	Older children/adults in specific risk groups
Dosage Volume	0.05 ml (newborns), 0.1 ml (others)	Variable in research settings (0.025-0.15 ml)
Needle Type	Short-beveled (26-27 gauge)	Standard subcutaneous needles (not recommended)
Storage Requirements	2-8°C, protected from light	Room temperature formulations (experimental)

Why It Matters

Global Health Impact: BCG vaccination prevents approximately 40,000 childhood tuberculosis deaths annually worldwide. The vaccine provides 50-80% protection against severe forms of childhood TB including tuberculous meningitis and miliary tuberculosis. In high-burden countries, universal neonatal vaccination has reduced childhood TB mortality by up to 70% since implementation.
Economic Benefits: Each dollar invested in BCG vaccination generates an estimated $30-50 in economic returns through prevented healthcare costs and productivity losses. The vaccine's low cost (approximately $0.16-$0.40 per dose) makes it one of the most cost-effective public health interventions available, particularly in resource-limited settings.
Non-Specific Effects: BCG vaccination provides heterologous protection against unrelated pathogens, reducing all-cause infant mortality by 25-45% in some studies. The vaccine trains innate immune cells through epigenetic reprogramming, enhancing response to subsequent infections. This "trained immunity" effect may last for months to years post-vaccination.

Looking forward, BCG vaccination remains essential while researchers develop more effective TB vaccines. Several next-generation candidates are in clinical trials, but BCG continues to provide crucial protection during this transition period. The vaccine's established safety profile and additional benefits position it as a cornerstone of global tuberculosis control strategies for the foreseeable future. Ongoing research into optimized administration techniques and timing may further enhance its effectiveness in diverse populations.